Search results
Results from the WOW.Com Content Network
Priority review vouchers are currently earned by pharmaceutical companies for the development and approval of drugs treating neglected tropical diseases, rare pediatric diseases, and "medical countermeasures" for terrorism. The voucher can be used for future drugs that could have wider indications for use, but the company is required to pay a ...
In May 2019, the privately held US company Jacobus Pharmaceutical, Princeton, New Jersey gained approval by the FDA for amifampridine tablets (Ruzurgi) for the treatment of LEMS in patients 6 to less than 17 years of age. This is the first FDA approval of a treatment specifically for pediatric patients with LEMS.
The FDA confirmed that the Viaskin Peanut patch satisfies the key criteria for Accelerated Approval, including addressing a serious condition and offering a meaningful advantage over existing ther
When the semaglutide medication Wegovy first hit the market in 2021, it became the first weight-loss drug to get FDA approval since 2014 and immediately became the go-to weight-loss treatment.
Based on findings from animal studies, selumetinib may cause harm to a newborn baby when administered to a pregnant woman. [14] The FDA advises health care professionals to tell women of reproductive age, and men with female partners of reproductive potential, to use effective contraception during treatment with selumetinib, and for one week after the last dose.
Kids Mineral Sunscreen. Think, a favorite of Dr. Maguiness, offers a kids sport sunscreen that's perfect for active summer days because its smooth formula goes on like a moisturizer.Thanks to the ...
According to pediatric endocrinology expert Brad Miller, pharmaceutical companies that make puberty blocker drugs for children with gender dysphoria have refused to submit them for FDA approval because doing so would cost too much money and "because (transgender treatment) was a political hot potato." [56]
The article 3 Companies Facing FDA Approval: Chelsea, MannKind, and Durata originally appeared on Fool.com. Brian Orelli , Max Macaluso , and The Motley Fool have no position in any of the stocks ...